Vivek Subbiah: The power of Tissue-Agnostic in Precision Medicine
Vivek Subbiah shared a post by Antonio Calles, Head, Lung Cancer Unit at Hospital Ruber Internacional, on X, adding:
“Great case to show the power of Tissue-Agnostic Precision Medicine.
That’s why we need tissue-agnostic drug approvals so patients with rare diseases can have access to these therapies.”
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Authors: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran and Yung-Jue Bang.
Quoting Antonio Calles:
“Even in ultra-rare tumors like this relapsed BRAF V600E-mutant metastasic malignant glomus tumor, tumor agnostic treatment with BRAF + MEK inhibitors encorafenib plus binimetinib led to complete response and long lasting benefit. Check out this case.”
Authors:
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023